Regulus Therapeutics Inc.
regulusrx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 8, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 8, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops drugs designed to block microRNAs for patients with kidney diseases, including polycystic kidney disease.
10-K for FY2024, filed Mar 13, 2025We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat…View ↗
We have assembled significant expertise in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a…View ↗
Farabursen is a novel oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney.…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 9, 2025
−$9.6MView ↗
- ▲ +14% (Loss)
- vs −$8.5M in Q1 FY2024
-
Jun 25, 2025
Novartis completed its acquisition of Regulus
Regulus became an indirect wholly owned subsidiary of Novartis after the merger.
Sources
8-K, filed Jun 25, 2025
On June 25, 2025, following consummation of the Offer, Parent completed the acquisition of the Company by causing Merger Sub to merge with…View ↗
A narrower focus
The older report described an Alport syndrome program transitioned to Sanofi alongside an ADPKD candidate; the latest report focuses on farabursen for ADPKD and its internal discovery pipeline.
10-K for FY2021, filed Mar 11, 2022 10-K for FY2024, filed Mar 13, 2025We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat…View ↗
Who Did They Compete With?
Competes with Otsuka Pharmaceutical, Xortx Therapeutics, Vertex, and PYC Therapeutics
10-K for FY2024, filed Mar 13, 2025Currently, there is one drug approved and several therapies in preclinical and clinical development for the treatment of patients with…View ↗
Loading...
